Get the Stockscreener App
32.83
1.48%
0.48
After Hours:
32.84
0.01
+0.03%
Maze Therapeutics Inc stock is traded at $32.83, with a volume of 548.48K.
It is up +1.48% in the last 24 hours and up +35.27% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$32.35
Open:
$32.5
24h Volume:
548.48K
Relative Volume:
0.76
Market Cap:
$1.82B
Revenue:
$2.50M
Net Income/Loss:
$-131.12M
P/E Ratio:
-11.55
EPS:
-2.8431
Net Cash Flow:
$-112.73M
1W Performance:
+10.02%
1M Performance:
+35.27%
6M Performance:
-18.68%
1Y Performance:
+170.87%
1-Day Range:
$31.87
$33.49
1-Week Range:
$29.41
$33.49
52-Week Range:
$12.44
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
32.83 | 1.79B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-10-26 | Initiated | Mizuho | Outperform |
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
View All
Maze Therapeutics Inc Stock (MAZE) Latest News
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) CEO’s family trusts sell 34,501 shares under 10b5-1 plan - Stock Titan
Enterprise value to EBITDA forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Form 144 Maze Therapeutics For: 1 July By Investing.com - Investing.com UK
Form 4 Maze Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise - Stock Titan
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares - Investing.com
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares By Investing.com - Investing.com South Africa
Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan - Stock Titan
MAZE (MAZE) trusts sell tens of thousands of common shares May–June 2026 - Stock Titan
Maze Therapeutics (MAZE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Enterprise value to revenue forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Maze Therapeutics (MAZE) Gains 2.18% as Shares Test Key Resistance at $30.5Volatility Stop - dars.gov.et
Price to book forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
Price to earnings forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Enterprise value to revenue forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? - Yahoo Finance
Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In? - Sahm
MAZE Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE) - TradingView
MAZE Stock Price, Quote & Chart - ChartMill
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan - Stock Titan
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mizuho Securities Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward - TipRanks
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Maze Therapeutics (MAZE) price target increased by 11.37% to 44.12 - MSN
Maze Therapeutics (MAZE) Gains 3.38% as Biotech Stock Tests Key Resistance LevelsFibonacci Entry Signals - dars.gov.et
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maze Therapeutics Inc (MAZE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MAZE Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressGuidance Revision Trend - newsline.com
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance
MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - lwvtexas.org
MAZE Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionEPS Revision Trend - newsline.com
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan
Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan
Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan
18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan
Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan
MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView
MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView
MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com
Maze Therapeutics Inc Stock (MAZE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maze Therapeutics Inc Stock (MAZE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Jul 01 '26 |
Sale |
29.90 |
14,609 |
436,864 |
0 |
| Coloma Jason V | Chief Executive Officer |
Jul 01 '26 |
Sale |
29.98 |
34,501 |
1,034,253 |
23,337 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):